BACKGROUND: Endogenous angiogenesis inhibitors act as natural negative feedback in the focal area during the neovascularization process, and have less interference on physiological angiogenesis, and thus fewer negative side-effects. These inhibitors are potential candidates to combine with or substitutes for current popular anti-angiogenesis treatments to have synergistic effect. In this study, the effects of recombinant endothelial growth inhibitor protein (rhEDI-8t), a novel endogenous protein originated from collagen VIII, was investigated on ocular neovascularization (NV). Endostatin, a well-identified endogenous angiogenesis inhibitor, was compared in parallel and served as a positive control. METHODS: The inhibitory effect of rhEDI-8t on vascular endothelial cells was evaluated by a human umbilical vascular endothelial cells (HUVEC) proliferation test and a bovine aortic endothelial cells (BAEC) migration experiment. The effect of rhEDI-8t on ocular NV was further investigated in mice with choroidal neovascularization (choroidal NV) induced by laser, ischemic retinopathy and transgenic mice with expression of VEGF in photoreceptors (rho/VEGF) respectively. RESULTS: RhEDI-8t inhibited the growth of HUVECs and migration of BAECs stimulated by basic fibroblast growth factor (bFGF). Mice intravitreally treated with rhEDI-8t showed a significant reduction of choroidal NV, retinal NV and subretinal NV. CONCLUSION: Endogenous angiogenesis inhibitor rhEDI-8t showed a potent anti-angiogenesis effect in both in vitro and in vivo experiments. It contributed to the suppression of ocular NV. The study suggested that rhEDI-8t could be a subsidiary potent therapeutic medicine in addition to anti-VEGF therapy in future clinical anti-angiogenesis treatment.
BACKGROUND: Endogenous angiogenesis inhibitors act as natural negative feedback in the focal area during the neovascularization process, and have less interference on physiological angiogenesis, and thus fewer negative side-effects. These inhibitors are potential candidates to combine with or substitutes for current popular anti-angiogenesis treatments to have synergistic effect. In this study, the effects of recombinant endothelial growth inhibitor protein (rhEDI-8t), a novel endogenous protein originated from collagen VIII, was investigated on ocular neovascularization (NV). Endostatin, a well-identified endogenous angiogenesis inhibitor, was compared in parallel and served as a positive control. METHODS: The inhibitory effect of rhEDI-8t on vascular endothelial cells was evaluated by a human umbilical vascular endothelial cells (HUVEC) proliferation test and a bovine aortic endothelial cells (BAEC) migration experiment. The effect of rhEDI-8t on ocular NV was further investigated in mice with choroidal neovascularization (choroidal NV) induced by laser, ischemic retinopathy and transgenic mice with expression of VEGF in photoreceptors (rho/VEGF) respectively. RESULTS:RhEDI-8t inhibited the growth of HUVECs and migration of BAECs stimulated by basic fibroblast growth factor (bFGF). Mice intravitreally treated with rhEDI-8t showed a significant reduction of choroidal NV, retinal NV and subretinal NV. CONCLUSION: Endogenous angiogenesis inhibitor rhEDI-8t showed a potent anti-angiogenesis effect in both in vitro and in vivo experiments. It contributed to the suppression of ocular NV. The study suggested that rhEDI-8t could be a subsidiary potent therapeutic medicine in addition to anti-VEGF therapy in future clinical anti-angiogenesis treatment.
Authors: M S Seo; N Kwak; H Ozaki; H Yamada; N Okamoto; E Yamada; D Fabbro; F Hofmann; J M Wood; P A Campochiaro Journal: Am J Pathol Date: 1999-06 Impact factor: 4.307
Authors: P C Colorado; A Torre; G Kamphaus; Y Maeshima; H Hopfer; K Takahashi; R Volk; E D Zamborsky; S Herman; P K Sarkar; M B Ericksen; M Dhanabal; M Simons; M Post; D W Kufe; R R Weichselbaum; V P Sukhatme; R Kalluri Journal: Cancer Res Date: 2000-05-01 Impact factor: 12.701
Authors: T Tobe; S Ortega; J D Luna; H Ozaki; N Okamoto; N L Derevjanik; S A Vinores; C Basilico; P A Campochiaro Journal: Am J Pathol Date: 1998-11 Impact factor: 4.307
Authors: Rui Z Bai; Yang Wu; Quan Liu; Ke Xie; Yu Q Wei; Yong S Wang; Kang Liu; Yan Luo; Jing M Su; Bing Hu; Ji Y Liu; Qiu Li; Ting Niu; Zhi W Zhao; Li Yang Journal: J Exp Clin Cancer Res Date: 2009-03-05
Authors: Yi Li; Jun Li; Yat Ming Woo; Zan Shen; Hong Yao; Yijun Cai; Marie Chia-Mi Lin; Wai Sang Poon Journal: BMC Cancer Date: 2017-02-13 Impact factor: 4.430
Authors: Asbiel Hasbum; Jaqueline Quintanilla; Juan A Amieva Jr; May-Hui Ding; Arkene Levy; Sue Anne Chew Journal: Future Med Chem Date: 2021-01-05 Impact factor: 3.808